Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them.

Ownership research and analyst forecasts data provide insights into stock opportunities. Institutions hold 37% stake in Trevi Therapeutics, impacting market cap fluctuations. Hedge funds and private equity firms also play significant roles in influencing company decisions.